TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04528719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection
Study: NCT04231175

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DWI MRI of the pelvis, abdomen and thorax
Description: Patients in Arm A will receive a MRI scan of their pelvis, abdomen, and thorax before possible surgery. During the MRI standard Gadolinium contrast agent and Buscopan is intravenously administered, which is standard clinical practice in abdominal MR imaging. Total scan time is 35 minutes and includes T2 weighted, T1 weighted, Diffusion weighted and dynamic contrast enhanced imaging of the abdomen and the thorax. The findings of this scan will be used to determine whether to proceed with CRS/HIPEC, DLS and then possibly CRS-HIPEC, or palliative care.
Study: NCT00487253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miltefosine
Description: Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
Study: NCT03292744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Description: alfacalcidol 0,5 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alfacalcidol
Description: alfacalcidol 0,5 mcg
Study: NCT02840019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: All participants will participate in an MRI scan. The add-on MRI scan will be 15 minutes. The full MRI scan will be 60 minutes.
Study: NCT01914289

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Study: NCT01807234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one spray in each nostril and placebo one nasal spray.
Study: NCT04036656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 2.5 mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 5 mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 10 mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 20 mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 35 mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 50 mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 0.5 mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 1 mg
Description: oral tablet
Study: NCT04528719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Formulation for injection
Study: NCT04036656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 2.5 mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 5 mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 10 mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 20 mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 35 mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SYHA136 50 mg
Description: oral tablet
Study: NCT01639040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab 300 mg once weekly (QW) for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Dupilumab)
Description: Placebo (for Dupilumab) once weekly (QW) for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid (TCS)
Description: TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid (TCS)
Description: TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%
Study: NCT02180282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22-IPL
Description: The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.~The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm.
Study: NCT01332942

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BAY85-3934
Description: Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
Study: NCT00981032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-visit Summary
Description: The intervention is a pre-visit summary given to the patient prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Sharing Tool
Description: This intervention includes a pre-visit summary and a clinical decision sharing tool. Patients will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
Study: NCT03601754

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Treadmill/Bicycle exercise testing
Description: Exercise testing will be scheduled on the same day as the enrollment visit and within 30 days after post-implant visit.~The standard protocol will be typically set at an initial workload of 15Watts and go up by increments of 10 Watts every 3 minutes, as follows:~Stage 1 - 15 W Stage 2 - 25 W Stage 3 - 35 W Stage 4 - 45 W
Study: NCT03504358

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.
Study: NCT01807234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo one spray in each nostril and placebo one nasal spray.
Study: NCT00886210

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intra abdominal drain
Description: Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
Study: NCT00886210

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LC without drain
Description: Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
Study: NCT00245518

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT01733550

Intervention type: DEVICE
Intervention: Home iCare (study nurse)
Description: the intraocular pressure is measured by iCare performed by the study nurse

Intervention type: DEVICE
Intervention: goldmann applanation tonometry
Description: the intraocular pressure is measured by goldmann applanation tonometry

Intervention type: DEVICE
Intervention: home iCare (by patient)
Description: the intraocular pressure is measured by the iCare performed by the patient him self
Study: NCT00233727

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HPV DNA Testing + Cryosurgery
Description: Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VIA + Cryosurgery
Description: Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women.
Study: NCT01074229

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug .5% Ropivacaine
Description: .5% ropivacaine 20 mls on each side of abdomen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 cc of 0.25% ropivacaine
Description: Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
Study: NCT03555617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473
Description: oral capsule/tablet, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473
Description: oral capsule/tablet, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473
Description: oral capsule/tablet, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: oral solution, QD
Study: NCT02791685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MULTIFIT Cardiac Rehabilitation
Description: MULTIFIT is a cardiac rehabilitation program delivered by the Movn smartphone application that will provide risk factor modification, prescribed exercises, education and counseling. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movn Pulmonary Rehabilitation
Description: Movn pulmonary rehabilitation is a program delivered by the Movn smartphone application that includes targeted educational content and prescribed exercises with mild resistance training in addition to walking and other cardiovascular exercises. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Cardiac Rehabilitation
Description: Standard cardiac rehabilitation involves a facility's standard rehabilitation practices. Participants will be seen at baseline and during a 12 and 24 week follow-up visit.
Study: NCT02197494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 320mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 320mg tablets
Study: NCT00042510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treatment group
Study: NCT03635801

Intervention type: DEVICE
Intervention: MyoVista 12 lead Electrocardiogram (ECG)
Description: MyoVista 12 Lead Electrocardiogram (ECG)
Study: NCT04078373

Intervention type: BEHAVIORAL
Intervention: Immediate urination
Description: Patients with decreased cognitive ability will be taught to immediately go to the toilet upon feeling the urge to urinate and to be independent in urinating.

Intervention type: BEHAVIORAL
Intervention: Bladder diary
Description: Patients with normal cognitive abilities will be instructed to go to the toilet every 2-3 hours regardless of the urge to urinate
Study: NCT00606892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline (1 mg per day) given for 4 days prior to laboratory session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline (1 mg per day) given for 4 days prior to laboratory session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar Pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar Pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Nic
Description: IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Nic
Description: IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
Study: NCT00234832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine hydrochloride
Description: One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine hydrochloride
Description: 10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
Study: NCT03672188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection
Study: NCT01258140

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Computed tomography pulmonary angiography
Description: CT pulmonary angiography using iodinated contrast agent

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Computed tomography pulmonary angiography
Description: CT pulmonary angiography using iodinated contrast agent
Study: NCT00793455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational outreach
Description: Participants will get a letter from their physician that explains that their records show the test has not been completed. The letter will be mailed along with an educational brochure and a DVD about colorectal cancer and colorectal cancer screening.
Study: NCT03902665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Up-front allogeneic hematopoietic stem cell transplantation (HSCT)
Description: Patients classified as fit/unfit are included in the HSCT program. There are two early approaches allowed. A) Patients will be left untreated until HSCT B) Patients will receive 1 short course of chemotherapy before HSCT (Ara-C and anthracycline).~Selection of strategy A or B, will be patient based on disease characteristics and dynamics or presence of high tumor load.~Conditioning for haplo-HSCT should be started as soon as possible, within day 45 after initial diagnosis. This is to avoid delayed transplantation. Two dosing levels of the Thiotepa-Busulfan-Fludarabine (TBF) based protocol are allowed based on the clinical condition of the patient: fit patients below 70 will receive the TBF with 2 days of Busulfan, whereas patients with poorer clinical condition or above the age of 70 will receive a dose-reduced TBF, in which Busulfan may be reduced to 1 day only.
Study: NCT03672188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection
Study: NCT01914289

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Study: NCT02924831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Stimulating acupoints by using stainless steel needles with manual manipulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Stimulating acupoints by using stainless steel needles with manual manipulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Stimulating acupoints by using stainless steel needles with manual manipulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moxibustion
Description: Stimulating acupoints by using burned moxa
Study: NCT03672188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection
Study: NCT02924831

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Stimulating acupoints by using stainless steel needles without manual manipulation.
Study: NCT01899339

Intervention type: OTHER
Intervention: submassive PA treatment with Ekosonic endo device
Description: Ultra Sound energy along with tPA to treat submassive pulmonary embolism
Study: NCT02478229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) and Ledipasvir (LDV)
Study: NCT04047992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego™ Exoskeleton
Description: The Indego® is a powered exoskeleton that can be used as a mode of therapy in an institutional setting. Proper walking in this device requires the user to manipulate their center of gravity and balance by postural trunk excursions in order for the legs to take steps.
Study: NCT02260661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8835
Description: AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8835
Description: AZD 8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8835 in combination with fulvestrant
Description: AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy.
Study: NCT01914289

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT03108664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL1001 ophthalmic solution
Description: 1 drop in the affected eye
Study: NCT02260661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8835 in combination with fulvestrant
Description: AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy
Study: NCT03857477

Intervention type: GENETIC
Intervention: Genetic SNP profiling
Description: Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.